Clinically Resectable Acinar Cell Carcinoma of the Pancreas: Is There a Benefit to Adjuvant Systemic Therapy?
ConclusionsAdjuvant therapy is associated with a significant survival benefit in patients with resectable acinar cell carcinoma.
Source: The American Journal of Surgery - Category: Surgery Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Legislation | Pancreas | Pancreatic Cancer | Study | Surgery